24/7 Market News Snapshot 30 September, 2025 – Nuvation Bio Inc. (NYSE:NUVB)

September 30, 2025

DENVER, Colo., 30 September, 2025 (www.247marketnews.com) – (NYSE:NUVB) are discussed in this article.
Nuvation Bio Inc. (NUVB) has opened today at $3.38 and is currently experiencing a notable uptick, trading at $3.72 after a 15.59% rise from the previous day’s close of $3.22. The stock’s trading volume is substantial at 8.13 million shares, indicating strong investor engagement and favorable market sentiment. This upward movement highlights potential positive developments related to the company’s pipeline. Investors are advised to keep an eye on resistance levels around $3.80 and support near $3.50 to strategize their positions effectively in this bullish market.

In a significant advancement in cancer treatment, Nuvation Bio has announced the enrollment of the first patient in its TRUST-IV Phase 3 clinical trial, which evaluates the efficacy of IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, for treating non-small cell lung cancer (NSCLC). This pivotal study aims to examine IBTROZI as an adjuvant therapy for patients with resected ROS1-positive early-stage NSCLC, a patient demographic that traditionally has limited post-surgery treatment options.

Despite surgical interventions, recurrence remains a challenging aspect for many diagnosed with early-stage NSCLC. Dr. Alexander Drilon, Chief of Early Drug Development at Memorial Sloan Kettering Cancer Center, asserts a pressing need for innovative therapies in this area. Taletrectinib, which has shown a robust safety profile and promising results in advanced cases, has the potential to significantly enhance patient outcomes in the early stages of the disease.

The TRUST-IV trial, aligned with guidelines from the U.S. Food and Drug Administration, aims to enroll around 180 participants who have undergone surgery and received standard postoperative chemotherapy, randomizing them to either receive taletrectinib or a placebo. The primary endpoint will focus on improving disease-free survival rates.

David Hung, M.D., Founder and CEO of Nuvation Bio, expressed optimism about this initiative, stating it represents a critical step in their commitment to developing transformative treatments for cancer patients. As Nuvation Bio works to expand its innovative pipeline, the industry watches closely, awaiting the trial outcomes that could redefine the standard of care for NSCLC.

Related news for (NUVB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.